<DOC>
	<DOC>NCT02741791</DOC>
	<brief_summary>To evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD). This is a randomized, double-blind, active-controlled, 12-week, two-period study consisting of an open-label, bupropion lead-in period, and a double-blind treatment period. The trial is being conducted in subjects with treatment resistant MDD. Subjects will be considered to have treatment resistant MDD if they have had a historical inadequate response to 1 or 2 antidepressant treatments and a prospective inadequate response to treatment with bupropion during the open-label, lead-in period.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Key Currently meets DSMV criteria for MDD History of inadequate response to 1 or 2 adequate antidepressant treatments Body mass index (BMI) between 18 and 40 kg/m2, inclusive Agree to use adequate method of contraception for the duration of the study Additional criteria may apply Key Suicide risk Treatment with any investigational drug within 6 months History of electroconvulsive therapy (ECT), vagus nerve stimulation, transcranial magnetic stimulation, or any experimental central nervous system treatment during the current episode or in the past 6 months Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>AXS-05</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Treatment Resistant Depression</keyword>
	<keyword>TRD</keyword>
	<keyword>MDD</keyword>
	<keyword>Axsome</keyword>
	<keyword>NMDA receptor</keyword>
	<keyword>Refractory depression</keyword>
	<keyword>Resistant depression</keyword>
	<keyword>Depression</keyword>
</DOC>